Related by context. All words. (Click for frequent words.) 68 TMC# C# 64 NSABP B 64 Quinamed 63 GOUT 63 BCIRG 63 treatment naive genotype 63 HCV SPRINT 63 ACCOMPLISH 62 LUX Lung 62 Sipuleucel T 62 APTIVUS 62 prospective multicentre 62 MINDSET 62 EURIDIS 62 Pegylated Interferon 61 ATTRACT 61 pharmacokinetic PK study 61 viral kinetics 61 IN PATIENTS WITH 61 relapsing multiple sclerosis 61 ritonavir boosted 61 refractory chronic lymphocytic 61 Initiate Phase 61 peg interferon 61 alfa 2a 61 placebo controlled Phase III 61 PEG IFN 61 tipranavir ritonavir 61 multicentre randomized 61 Initiated Phase 60 PREZISTA r 60 LEXIVA r 60 Peginterferon 60 HuMax EGFr 60 efavirenz EFV 60 phase IIIb 60 Prospective Randomized 60 Oral Fingolimod 60 CCR5 tropic HIV 60 Randomized Phase 60 APPRAISE 60 null responder HCV 60 ORENCIA ® 60 Phase 1a clinical 60 dose escalation clinical 60 Copegus ribavirin 60 placebo controlled Phase 60 Chronic Heart Failure 60 boosted protease inhibitor 60 PHASE III 60 RIBBON 60 Phase Ib clinical 60 ascending dose 60 HBeAg negative 60 See CLINICAL PHARMACOLOGY 59 HCV Genotype 59 Complicated Skin 59 PATIENTS WHO 59 relapsed MM 59 certolizumab 59 TO AVOID PREGNANCY WHILE 59 pegylated interferon alfa 2a 59 forodesine 59 Antiviral Therapy 59 RADIANT 59 ribavirin RBV 59 celgosivir 59 interferon gamma 1b 59 tipranavir 59 AIR2 Trial 59 bortezomib Velcade R 59 AVASTIN 59 Glufosfamide 59 SELZENTRY 59 RE MODEL 59 Elitek 59 ASSERT 59 HGS# 59 multicenter phase 59 IIa clinical 59 BOLDER 59 postmenopausal osteoporotic women 59 BOLDER II 59 ACTEMRA TM 59 novel VDA molecule 59 BARACLUDE ® 59 FDA APPROVES 59 sorafenib tablets 59 Protease Inhibitor 59 BRIM3 59 PREVAIL 59 Interferon beta 1a 59 multicenter randomized controlled 59 REYATAZ ® 59 randomized multicenter 58 multicenter randomized placebo controlled 58 oral FTY# 58 Pertuzumab 58 phase IIb 58 XL# SAR# 58 ILLUMINATE 58 Naive Patients 58 CIMZIA TM certolizumab pegol 58 DEFER 58 Aflibercept 58 Truvada tablets 58 Betaferon R 58 evaluating Actimmune 58 Aptivus ® 58 VAX# 58 ER CHOP 58 CHAMPION PCI 58 farletuzumab 58 Relapsed Refractory 58 sunitinib malate 58 Pemetrexed 58 protease inhibitor PI 58 Tipranavir 58 Multicentre 58 VICTOR E1 58 Taxotere ® 58 mildly symptomatic 58 Multicenter 58 peginterferon alfa 2b 58 Chronic Hepatitis C 58 evaluating carfilzomib 58 Trial Evaluating 58 Randomized Phase II 58 Blinatumomab 58 Intervention Effectiveness 58 Phase IIIb 58 YONDELIS 58 inhibitor RG# 58 Xelox 58 4mg/kg 58 UNLOAD 58 dual endothelin receptor antagonist 58 recurrent glioma 58 AVONEX ® 58 OUTCOMES 58 tanespimycin 58 phase IIa 58 ENVISION 58 lopinavir r 58 Phase 2b Study 58 Natalizumab 58 Randomized Evaluation 58 sorafenib Nexavar 58 TRANSFORMS 58 velafermin 58 APTIVUS r 58 trastuzumab Herceptin R 58 ISTODAX ® 58 evaluating tivozanib 58 SORT OUT 58 plus COPEGUS 58 Phase 1b trial 58 Tanespimycin 58 INITIATE 58 ASTEROID 57 Bosutinib 57 Clinical Antipsychotic Trials 57 randomized controlled Phase 57 PROSTVAC VF 57 Phase Ib II 57 HIV RNA 57 Pivotal Phase 57 Study Evaluating 57 atazanavir sulfate 57 Acute Ischemic Stroke 57 canakinumab 57 Antiretroviral Therapy 57 APTIVUS R 57 Follicular Lymphoma 57 Femara letrozole 57 Prostate AdenoCarcinoma Treatment 57 DermaVir Patch 57 phase Ib 57 RoACTEMRA 57 alvespimycin 57 designated HVTN 57 Pegasys plus Copegus 57 neratinib 57 Cutaneous T 57 TMC# r 57 REVIVE 57 Multiple Ascending Dose 57 STENT 57 fludarabine cyclophosphamide 57 Pegasys ® 57 Randomized controlled 57 TREATMENT OF 57 HBsAg 57 CLARITY TIMI 57 STUDY RESULTS 57 Trandolapril 57 DURATION 57 registrational Phase 57 CIMZIA TM 57 metastatic neuroendocrine tumors 57 Neoadjuvant 57 DIAGNOSTIC 57 multicentre 57 RE LY 57 IRESSA 57 Pooled Analysis 57 HORMONE 57 TDF FTC 57 HCV genotype 57 CIMZIA ™ 57 antibody MAb 57 CATIE AD 57 NSABP 57 genotypic resistance 57 Vicriviroc 57 Prospective Randomized Trial 57 Alocrest 57 Dacogen injection 57 TYKERB 57 darunavir ritonavir 57 NOX E# 57 Kivexa 57 PREZISTA ritonavir 57 antiretroviral naïve 57 CORD II 57 Eluting Stent 57 nucleotide analogue 57 adjuvant trastuzumab 57 Pharmacokinetics PK 57 candesartan cilexetil 57 ARDIS 57 Multicenter Phase 57 blinded randomized placebo controlled 57 THAT ARE DIFFICULT TO 57 VELCADE melphalan 57 adalimumab 57 fosbretabulin 57 Meets Primary Endpoint 57 Phase III Clinical Trial 57 MEDICATIONS 57 Safinamide 57 ZACTIMA 57 dose escalation trial 57 Phase IIb Trial 57 abacavir lamivudine 57 CALGB 57 relapsing remitting MS RRMS 57 PegIFN 57 BRIM2 56 vidofludimus 56 Phase 1b clinical 56 PRECiSE 56 Phase 1b 56 pegylated interferon alfa 2b 56 treatment naïve genotype 56 LUNG CANCER 56 CANCERS 56 biologic DMARD 56 tenofovir emtricitabine 56 recurrent glioblastoma multiforme 56 AIDS Clinical Trials 56 #mg BID [001] 56 multicenter prospective 56 pramlintide metreleptin combination 56 HYPERTENSION 56 TLK# 56 randomized Phase III 56 Hormone Refractory Prostate Cancer 56 Vitaxin 56 Nesiritide 56 #mg QD [002] 56 Phase III randomized controlled 56 Azacitidine 56 IFN alfa 56 Capesaris 56 PREGNANT WOMEN 56 FASLODEX 56 lopinavir ritonavir Kaletra 56 darunavir r 56 atazanavir ritonavir 56 Telmisartan 56 Plicera 56 trastuzumab emtansine T DM1 56 diarrhea predominant irritable 56 rALLy clinical trial 56 Phase IIIb clinical 56 GW# [003] 56 Pharmacokinetic Study 56 FOLOTYN ® 56 metastatic castration resistant 56 prospective nonrandomized 56 pertuzumab 56 abacavir Ziagen 56 RECORD1 56 phase IIa clinical 56 vicriviroc 56 8mg/kg 56 docetaxel Taxotere ® 56 Hsp# Inhibitor 56 Phase #/#a 56 TELCYTA 56 placebo controlled clinical 56 Pegylated Liposomal Doxorubicin 56 ENABLE 56 RECOMMENDED FOR 56 Phase 2b Trial 56 melphalan prednisone 56 Sorafenib HCC Assessment 56 Adalimumab 56 pegylated interferon alpha 56 Randomised 56 Peg IFN 56 glatiramer acetate 56 galiximab 56 XIENCE V Stent System 56 relapsed refractory multiple myeloma 56 R#/MEM # 56 Vidaza azacitidine 56 Phase III randomized 56 HBeAg negative patients 56 Percutaneous Tibial Nerve Stimulation 56 unfractionated heparin UFH 56 Observational Study 56 Combination REOLYSIN R 56 OHR/AVR# 56 QD dosing 56 oral prodrug 56 ONCOLOGY 56 Drug Eluting Stent System 56 HBeAg positive 56 Successfully Completes Phase 56 INTELENCE 56 chronic HCV infection 56 Cloretazine 56 oral ridaforolimus 56 LAB CGRP 56 MMX mesalamine 56 NCT# ClinicalTrials.gov 56 Aggressive Drug Evaluation 56 Advanced Renal Cell 56 PSMA ADC 56 ISENTRESS 56 pharmacokinetic pharmacodynamic 56 ug dose 56 standard chemotherapy regimen 56 MATCHED 56 basal bolus regimen 56 HCV genotypes 56 Phase IIA 56 trials RCTs 56 Inhalation Solution 56 RezularTM 56 RhuDex 56 CALGB # [002] 56 registrational trial 56 mRCC 56 ACCLAIM 56 assessing T DM1 56 KRN# 56 peginterferon alpha 2a 56 II Clinical Trial 56 gemcitabine carboplatin 56 Liraglutide Effect 56 ORMD 56 depsipeptide 56 SANTE 56 metastatic castrate resistant 56 ARIXTRA R 56 prospective observational cohort 56 teriflunomide 56 GAMMAGARD 56 pioglitazone HCl 56 Darunavir 56 Mycophenolate Mofetil 56 GELA 55 PROMACTA 55 REVIVE Diabetes 55 alpha 2a 55 Phase Ib Clinical Trial 55 Confirmatory Phase 55 THYROID 55 Ozarelix 55 INCB# [001] 55 stage IIIB 55 mg/m2 dose 55 multicenter Phase 55 Phase #b/#a clinical 55 nucleotide analog 55 adjuvant endocrine therapy 55 Ocrelizumab 55 ibandronate 55 Epirubicin 55 Phase III Pivotal 55 Platinol ® 55 antiretroviral naive 55 EOquin TM 55 Tocilizumab 55 ancrod 55 Pivotal Study 55 Randomized Study 55 pharmacokinetic PK 55 TRO# 55 Sapacitabine 55 randomized multicenter trial 55 denileukin diftitox 55 Randomized Controlled 55 Rasilamlo 55 trastuzumab Herceptin ® 55 Castration Resistant Prostate Cancer 55 tipranavir r 55 Phase 2a Trial 55 NO# [002] 55 Dose Escalation 55 oxycodone CR 55 peginterferon 55 satraplatin Phase 55 PRECISE 55 virologic 55 dose escalation Phase 55 prospective multicenter 55 telaprevir dosed 55 MGd 55 STRIDE PD 55 painful diabetic neuropathy 55 Phase III Trial 55 desvenlafaxine succinate 55 Daclizumab 55 hA# 55 doxorubicin docetaxel 55 NOVARTIS 55 AEGR 55 Phase Ib clinical trials 55 retrospective cohort 55 ASSURE 55 Phase 2b Clinical Trial 55 phase IIb clinical 55 SUTENT ® 55 OvaRex MAb 55 Aptivus 55 metastatic GIST 55 PRoFESS 55 tenofovir FTC 55 de novo kidney transplant 55 cisplatin gemcitabine 55 pyridostigmine 55 HGS ETR2 55 INFORM 55 oral deforolimus 55 ceftazidime 55 Ranolazine 55 clevidipine 55 Decitabine 55 R roscovitine 55 randomized #:#:# 55 Dasatinib 55 constipation OIC 55 MORTALITY 55 CARRA 55 crizotinib PF # 55 Phase IIb III 55 CCX# B 55 ONTARGET 55 CTAP# Capsules 55 AZILECT R 55 Cardiac Allograft Rejection 55 HALTS 55 zidovudine lamivudine 55 Late Onset 55 severe oral mucositis 55 MEND CABG II 55 plus dexamethasone 55 AIM HIGH 55 brivaracetam 55 MERLIN TIMI 55 PRE SURGE 55 ixabepilone 55 prospectively randomized 55 metastatic malignant 55 Phase 2b kidney transplant 55 Clinical Trial Results 55 Clinical Outcomes Utilizing Revascularization 55 HER2 positive metastatic breast 55 Schizophrenia Treatment 55 pan HDAC inhibitor 55 Randomized trials 55 q#h 55 Imprime PGG 55 RE LY ® 55 Gastric Cancer 55 TQT 55 Acute Decompensated Heart Failure 55 Telzir 55 Non Alcoholic Steatohepatitis 55 Epratuzumab 55 pegylated liposomal doxorubicin 55 IFN α 55 Recurrent Glioblastoma 55 HORIZONS AMI trial 55 decitabine 55 Controlled Trial 55 Left Ventricular Dysfunction 55 mapatumumab 55 TRAINING PROGRAMME 55 YERVOY 55 LymphoStat B belimumab 55 ULORIC 55 double blinded randomized 55 QLT# 55 Proellex TM 55 XELOX 55 fostamatinib 55 TMC# [001] 55 fluvastatin 55 EDEMA3 55 lumiliximab 55 Chemoradiation 55 Vandetanib 55 refractory AML 55 iPrEx 55 mcg dose 55 plus prednisone 55 REYATAZ R 55 ATTAIN 55 nucleoside analog 55 tocilizumab 55 Gynecologic Oncology Group 55 Lenalidomide 55 Ophena 55 Advaxis Phase 55 Lymphocytic 55 Diabetic Macular Edema 55 Intervention Trial 55 multicentre randomized double 55 number NCT# ClinicalTrials.gov 54 GISSI 54 TORISEL TM 54 FTC TDF 54 ORENCIA R 54 trabectedin 54 DAPT 54 saquinavir ritonavir 54 glulisine 54 Saquinavir 54 Bayer HealthCare Onyx Pharmaceuticals 54 myelodysplastic syndromes MDS 54 Tarceva TM 54 ISEL 54 Ovarian PLCO Cancer 54 Apaziquone 54 Nilotinib 54 mild hepatic impairment 54 AVADO 54 evaluating REVLIMID 54 Torisel 54 rindopepimut 54 stavudine d4T 54 LUMINATE 54 nucleoside naive 54 Folfox 54 label multicenter Phase 54 Oral NKTR 54 HCV infected 54 Treatment Naive HIV 54 multicenter Phase II 54 nitazoxanide 54 PEGylated interferon 54 cinacalcet 54 BCG refractory 54 Sprycel dasatinib 54 ADVANCE PD 54 sargramostim 54 Phase 2a clinical 54 refractory CLL 54 MVA MUC1 IL2 54 μg dose 54 NOD SCID mice 54 CBLC# 54 clinical pharmacology studies 54 Clinical Trial Investigating REOLYSIN 54 ACZ# 54 IIa trial 54 CanAg 54 REG2 54 lintuzumab 54 peginterferon alfa 2a 54 HIV uninfected 54 docetaxel Taxotere R 54 vorinostat 54 tenofovir Viread 54 amisulpride 54 investigational protease inhibitor 54 R#/MEM 54 Velcade bortezomib 54 prospective randomized controlled 54 myelodysplastic myeloproliferative diseases 54 Tumor Response 54 ECASS 54 Efficacy Trial 54 metastatic renal cell carcinoma 54 virologically suppressed 54 AVANDIA 54 active comparator 54 Nebulized 54 Vacc 4x 54 aripiprazole Abilify 54 humanized interleukin 6 54 insulin glulisine 54 AVENTIS 54 virus HBV 54 Keryx Biopharma 54 elacytarabine 54 Dual Opioid 54 Phase IIa Clinical Trial 54 NCIC CTG 54 dose escalation study 54 Protelos 54 suboptimal adherence 54 Pivotal Phase III 54 apricitabine 54 relapsed multiple myeloma 54 elotuzumab 54 EQUETRO 54 DEB# 54 ChronVac C ® 54 clodronate 54 thorough QT 54 BENICAR HCT 54 Clolar ® 54 Aggressive Reduction 54 ATACAND 54 erlotinib Tarceva ® 54 Exelixis XL# 54 Ixempra 54 prospective randomized multicenter 54 Brentuximab Vedotin SGN 54 PSORIASIS 54 Irinotecan 54 LHRH receptor positive 54 Testosterone MDTS ® 54 daunorubicin 54 Fondaparinux 54 dosing cohorts 54 Patient Registry 54 Diabetic Macular Edema DME 54 placebo controlled dose escalation 54 Phase 2a trial 54 EOquin TM phase 54 -#.# log# 54 liposomal formulation 54 riociguat 54 COPAXONE 54 evaluating Nexavar 54 custirsen 54 Phase III multicenter 54 Aplidin R 54 Raptiva ® 54 HDAC Inhibitor 54 blinded placebo controlled 54 selective modulator 54 Pazopanib 54 corifollitropin alfa 54 ongoing Phase 1b 54 virus HCV protease inhibitor 54 adriamycin 54 APEX PD 54 Fabry Disease 54 virologic failure 54 #mg BID [003] 54 Intervention Effectiveness CATIE 54 Initiates Phase 54 hepatitis C genotype 54 MYLOTARG 54 Edge STudy 54 Allovectin 7 54 epigenetic therapies 54 Rebif ® 54 zidovudine AZT 54 d4T stavudine Zerit 54 Phase 1a 54 Denufosol 54 VFEND 54 Traficet EN 54 ROTATEQ 54 adjuvant tamoxifen 54 HCV RESPOND 2 54 doxorubicin cyclophosphamide 54 Endarterectomy 54 AVAiL 54 non nucleoside HCV 54 Prospective Multicenter 54 ABVD 54 multicenter clinical 54 Phase Ia 54 MEDICAL INFORMATION 54 phase IIb study 54 TMC# [002] 54 peginterferon alfa 54 Celgosivir 54 Infected Patients 54 nucleoside analogue 54 ARIXTRA 54 multicenter placebo controlled 54 CIPN 54 GLOBAL FUND 54 TORISEL 54 GetGoal Phase III 54 chemoradiation therapy 54 dose melphalan 54 dasatinib Sprycel ® 54 Ranibizumab 54 Degarelix 54 Temsirolimus 54 LibiGel ® 54 ID NCT# 54 adalimumab Humira 54 PRADAXA 54 Amigal 54 Trastuzumab 54 icatibant 54 Phase Ib IIa 54 Omacetaxine 54 Panzem R NCD 54 oral rivaroxaban 54 low dose cytarabine 54 mcg BID 54 MAGE A3 ASCI 54 Trial PCPT 54 OncoVEX GM CSF 54 Candesartan 54 mutated K ras 54 prucalopride 54 sunitinib 54 PERSEUS 54 CLINICAL PHARMACOLOGY 54 castrate resistant prostate cancer 54 ELACYT 54 Phase III Clinical Trials 54 randomized Phase IIb 54 MAGE A3 54 cetuximab Erbitux ® 54 vinca alkaloid 54 pegylated interferon alfa 54 Autologous Stem Cell Transplantation 54 AZILECT ® 54 JAK inhibitor 54 somatostatin analog 54 Etravirine 54 sustained virological response 54 Kinoid 54 refractory prostate cancer 54 Posaconazole 54 genotype 1a 54 NOXAFIL 54 STRATEGIC ALLIANCE 54 REYATAZ r 54 Non inferiority 54 gemcitabine Gemzar ® 54 docetaxel chemotherapy 54 lutropin alfa 54 PROSTATE 54 plus ribavirin 54 EMRG VIO 54 CR# vcMMAE 54 vandetanib 54 Virulizin ® 53 Afatinib 53 Group ECOG 53 YONDELIS R 53 Telbivudine 53 Hypoactive Sexual Desire Disorder 53 SUFFERERS 53 pomalidomide 53 chemotherapy cisplatin 53 ABILITY TO 53 PROCEED 53 Archexin 53 Onrigin 53 Val HeFT 53 nelfinavir 53 AZT zidovudine Retrovir 53 observational cohort 53 REMINYL ® 53 AIR CF1 53 AWAY DAY 53 BLOOD SUGAR 53 Elagolix 53 Phase IIb Clinical Trial 53 Adjunctive 53 CANCER DRUG 53 TPV r 53 factorial design 53 ASPECTS 53 ThermoDox R 53 plus methotrexate 53 irbesartan 53 controlled multicenter Phase 53 CombAT 53 phase IIb III 53 IgG1 antibody 53 suppressive therapy 53 Exforge HCT 53 NCCTG 53 RE SURGE 53 Bezielle 53 Viral load 53 cilengitide 53 Abatacept 53 metastatic hormone refractory 53 mcg linaclotide 53 micafungin 53 oral diclofenac 53 Initiates Clinical 53 HER2 antibody 53 Decompensated Heart Failure 53 CRLX# 53 Antiretroviral Treatment 53 dirucotide MBP# 53 temozolomide TMZ 53 -#.# log# copies mL 53 lamivudine zidovudine 53 comparator arm 53 TAXUS ATLAS 53 Metastatic Melanoma 53 Phase Ib 53 INSPIRE Trial Phase III 53 NO FUTURE 53 Aplidin 53 Sustiva efavirenz 53 5-FU/LV 53 ILLUSTRATE 53 antiviral efficacy 53 trastuzumab Herceptin 53 non metastatic osteosarcoma 53 HORIZONS 53 solithromycin 53 chemotherapeutic regimen 53 Betaferon ® 53 bosentan 53 atazanavir Reyataz 53 ExTRACT TIMI 53 NRTI 53 NATRECOR R 53 CCR5 mAb 53 AVONEX PEN 53 Sanofi aventis EURONEXT SAN 53 Virologic 53 IMA# 53 multicenter randomized clinical 53 Pivotal Trial 53 administered subcutaneously 53 Dacogen decitabine 53 sipuleucel T 53 Pneumococcal Vaccine 53 Myelofibrosis 53 CCR5 antagonist 53 refractory acute myeloid 53 pain palliation 53 evaluating mipomersen 53 Raptiva R 53 oral PrEP 53 multiple myeloma MM 53 Prostate Lung Colorectal 53 symptomatic BPH 53 Phase IIa trials 53 plasma renin activity 53 BCR ABL inhibitor 53 subcutaneously administered 53 EndoTAG 53 carboplatin paclitaxel 53 TASKi2 53 CAPRISA 53 pharmacodynamic PD 53 mg administered orally 53 RRMS patients 53 #mg QD [001] 53 epoetin alpha 53 Phase IIB 53 platelet inhibitor 53 rilpivirine 53 advanced metastatic renal 53 sustained virologic response 53 VADT 53 immunomodulatory therapies 53 MEND CABG 53 recurrent metastatic 53 EFFEXOR XR 53 refractory gout 53 LAMICTAL 53 nonnucleoside reverse transcriptase inhibitors 53 Zemplar Capsules 53 DESIRED 53 Clinical Trial Evaluating 53 Pre Exposure Prophylaxis 53 favorable pharmacokinetic profile 53 fluoropyrimidine 53 clinical trial 53 Achieves Primary Endpoint 53 baseline HbA1c 53 serum lipid levels 53 dependent kinase inhibitor 53 rFSH 53 BENICAR 53 Flu Cy 53 multicenter randomized 53 Antiretroviral ARV 53 Stent Thrombosis 53 Arranon 53 Isentress raltegravir 53 COMPARE 53 Pafuramidine 53 metformin XR 53 ganetespib 53 retrospective observational study 53 Teflaro treated 53 Fingolimod 53 interferon ribavirin 53 NEW DRUG 53 HGS ETR1 53 BENLYSTA ® 53 BZA CE 53 HIV HCV coinfected 53 Vidofludimus 53 prospective observational 53 Viral Load 53 masked placebo controlled 53 Cloretazine ® 53 cediranib 53 severe neutropenia 53 paclitaxel poliglumex 53 HBeAg 53 EVEREST II 53 grade cervical intraepithelial 53 ocrelizumab 53 Ziprasidone 53 DASISION 53 Sequenced Treatment Alternatives 53 dosage regimens 53 COMBIVIR 53 paclitaxel Taxol 53 Ceplene/IL-2 53 Acute Myocardial Infarction 53 CANCIDAS 53 dapagliflozin plus 53 Lung Cancer Trial 53 BR.# 53 LPV r 53 neoadjuvant 53 acyclovir Lauriad R 53 everolimus eluting stents 53 GASTRIC 53 tacrolimus ointment 53 recurrent glioblastoma 53 dose cytarabine 53 Ofatumumab 53 multicenter randomized double 53 Phase #/#a trial 53 SPIRIT FIRST 53 IMPACT DCM 53 paclitaxel Taxol ® 53 Roche Xeloda 53 Elacytarabine 53 ANTIBIOTICS 53 DermaVir 53 SNT MC# 53 Rigel R# 53 IMiDs ® compound 53 salmeterol fluticasone propionate 53 multicenter Phase III 53 atazanavir 53 hereditary medullary thyroid 53 ACTIVE W 53 DUTY TO 53 estramustine 53 Removab 53 pharmacokinetics PK 53 adjunctive placebo 53 FOLFIRI 53 pivotal Phase 53 Placebo controlled 53 Phase #b/#a 53 Platinol ® cisplatin 53 glucocorticoid induced osteoporosis 53 ENESTnd 53 omacetaxine mepesuccinate 53 Romiplostim 53 thromboembolic disease 53 PKC# 53 TBC# 53 AEG# 53 sunitinib Sutent 53 Pharmacokinetic PK 53 SIDE EFFECTS CHEAP ONLINE 53 ACHIEVE 53 PEG Interferon lambda 53 acyclovir Lauriad ® 53 Ribavirin 53 intermittent dosing 53 amprenavir 53 PROTEGE